Premium
Determination of calycosin‐7‐ O ‐ β ‐ d ‐glucopyranoside in rat plasma and urine by HPLC
Author(s) -
Ye Guan,
Ma RongRong,
Li ZhiXiong,
Wang Hui,
Zhu HaiYan,
Sun ZhaoLin,
Huang ChengGang
Publication year - 2007
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.819
Subject(s) - chemistry , chromatography , high performance liquid chromatography , calycosin , detection limit , urine , rutin , standard curve , extraction (chemistry) , pharmacokinetics , pharmacology , biochemistry , formononetin , medicine , daidzein , genistein , antioxidant
A reversed‐phase high‐performance liquid chromatographic (HPLC) assay for calycosin‐7‐ O ‐ β ‐ d ‐glucopyranoside in rat plasma and urine with solid‐phase extraction (SPE) was developed. Rutin was employed as an internal standard. The mobile phase consisted of acetonitrile–water (16:84, v/v) at a flow rate of 1.0 mL/min. Detection was set at 280 nm. The limit of quantitation of calycosin‐7‐ O ‐ β ‐ d ‐glucopyranoside was 0.2 µg/mL in both plasma and urine. The standard curve was linear from 0.2 to 10.0 µg/mL in plasma, and 0.2 to 5.0 µg/mL in urine. Both intra‐ and inter‐day precision of the calycosin‐7‐ O ‐ β ‐ d ‐glucopyranoside were determined and their RSD did not exceed 10%. The method was successfully applied to the analysis of samples obtained from a basic pharmacokinetic study, in which calycosin‐7‐ O ‐ β ‐ d ‐glucopyranoside was administered orally to rats. Copyright © 2007 John Wiley & Sons, Ltd.